These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25420535)

  • 1. Modeling anaplastic thyroid carcinoma in the mouse.
    Champa D; Di Cristofano A
    Horm Cancer; 2015 Feb; 6(1):37-44. PubMed ID: 25420535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.
    Vanden Borre P; McFadden DG; Gunda V; Sadow PM; Varmeh S; Bernasconi M; Jacks T; Parangi S
    Thyroid; 2014 Apr; 24(4):705-14. PubMed ID: 24295207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy: a new hope for thyroid carcinomas.
    Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
    Santarpia L; El-Naggar AK; Cote GJ; Myers JN; Sherman SI
    J Clin Endocrinol Metab; 2008 Jan; 93(1):278-84. PubMed ID: 17989125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathology and genetics of thyroid carcinoma.
    DeLellis RA
    J Surg Oncol; 2006 Dec; 94(8):662-9. PubMed ID: 17131411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing.
    Sykorova V; Dvorakova S; Vcelak J; Vaclavikova E; Halkova T; Kodetova D; Lastuvka P; Betka J; Vlcek P; Reboun M; Katra R; Bendlova B
    Anticancer Res; 2015 Apr; 35(4):2029-36. PubMed ID: 25862857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors.
    Antico Arciuch VG; Russo MA; Dima M; Kang KS; Dasrath F; Liao XH; Refetoff S; Montagna C; Di Cristofano A
    Oncotarget; 2011 Dec; 2(12):1109-26. PubMed ID: 22190384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Creation and characterization of a doxycycline-inducible mouse model of thyroid-targeted RET/PTC1 oncogene and luciferase reporter gene coexpression.
    Knostman KA; Venkateswaran A; Zimmerman B; Capen CC; Jhiang SM
    Thyroid; 2007 Dec; 17(12):1181-8. PubMed ID: 18004977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
    Albarel F; Conte-Devolx B; Oliver C
    Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and characterization of cell lines from a novel mouse model of poorly differentiated thyroid carcinoma: powerful tools for basic and preclinical research.
    Dima M; Miller KA; Antico-Arciuch VG; Di Cristofano A
    Thyroid; 2011 Sep; 21(9):1001-7. PubMed ID: 21767142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas.
    Rodrigues R; Roque L; Espadinha C; Pinto A; Domingues R; Dinis J; Catarino A; Pereira T; Leite V
    Oncol Rep; 2007 Oct; 18(4):917-26. PubMed ID: 17786355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability.
    Cantisani MC; Parascandolo A; Perälä M; Allocca C; Fey V; Sahlberg N; Merolla F; Basolo F; Laukkanen MO; Kallioniemi OP; Santoro M; Castellone MD
    Oncotarget; 2016 May; 7(19):28510-22. PubMed ID: 27058903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model.
    Zhu X; Kim DW; Zhao L; Willingham MC; Cheng SY
    Endocr Relat Cancer; 2016 Jul; 23(7):521-33. PubMed ID: 27267120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast-Mediated Collagen Remodeling Within the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by BrafV600E and Pten Loss.
    Jolly LA; Novitskiy S; Owens P; Massoll N; Cheng N; Fang W; Moses HL; Franco AT
    Cancer Res; 2016 Apr; 76(7):1804-13. PubMed ID: 26818109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
    Liu Z; Hou P; Ji M; Guan H; Studeman K; Jensen K; Vasko V; El-Naggar AK; Xing M
    J Clin Endocrinol Metab; 2008 Aug; 93(8):3106-16. PubMed ID: 18492751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathology of thyroid cancer: diagnostic and clinical implications.
    Fagin JA; Mitsiades N
    Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):955-69. PubMed ID: 19041825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF is a therapeutic target in aggressive thyroid carcinoma.
    Salvatore G; De Falco V; Salerno P; Nappi TC; Pepe S; Troncone G; Carlomagno F; Melillo RM; Wilhelm SM; Santoro M
    Clin Cancer Res; 2006 Mar; 12(5):1623-9. PubMed ID: 16533790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.